期刊文献+

血浆置换在溶血尿毒综合征治疗中的应用 被引量:3

Application of plasma exchange in the treatment of hemolytic uremic syndrome
原文传递
导出
摘要 目的探讨血浆置换在治疗溶血尿毒综合征(hemolyticuremicsyndrome,HUS)中的意义。方法对本院2008年1月至2010年12月收治的16例HUS患儿进行血浆置换治疗;以新鲜冰冻血浆作置换液,治疗时间每次2—3h。结果16例患儿经血浆置换治疗均存活,无明显并发症出现。全部患儿首次治疗后病情明显缓解;12—72h,黄疸消失,血肌酐[(385.0±189.4)μmol/LVS(100.0±19.3)μmol/L]、乳酸脱氢酶明显下降[(799.3±289.8)U/LVS(300.0±100.4)U/L],血小板计数[(45.0±18.8)×109/LVS(120.0±20.0)×109/L]、血红蛋白回升[(59.3±15.3)g/L VS(120.0±18.3)g/L],差异均有统计学意义(P〈0.05)。出院时15例患儿症状消失,14例实验室检查正常。住院时间为15~57d。结论血浆置换可以有效缓解病情,清除血浆致病物质,及时阻断HUS的病理过程,补充血浆中有效成分。推荐血浆置换作为治疗HUS的首选治疗方案。 Objective To investigate the significance of plasma exchange (PE) treatment on children with hemolytic uremic syndrome (HUS). Methods From Jan 2008 to Dec 2010,16 patients diagnosed with HUS were included in this study, and PE was carried out on them. Frozen plasma was taken as replacement flu- id,and the treatment time was 2 to 3 hours per time. Results All the 16 patients after PE treatment were sur- vived without any apparent complications. The condition obviously alleviated after initial treatment. In 12 to 72 hours ,the ictems disappeared, serum creatinine [ ( 385.0 ±189.4 ) μmol/L vs ( 100. 0 ± 19. 3 )μmol/L ] and lactate dehydrogenase [ ( 799. 3 ± 289. 8 ) U/L vs ( 300. 0 ± 100. 4 ) U/L ] declined obviously ( P 〈 0. 05 ) and platelet count [ (45.0 ± 18. 8) × 109/L vs ( 120. 0 ± 20. 0) × 109/L] , hemoglobin [ (59. 3± 15. 3 ) g/L vs ( 120. 0 ± 18.3 ) g/L] fised( P 〈 0. 05 ). In the end, symptoms disappeared in 15 patients, laboratory examination returned to normal in 14 cases. Hospitalization time was 15 to 57 days. Conclusion PE can effectively relieve the illness and remove plasma pathogenic substances ,block the pathological process of HUS and supply useful ingredients. Recommend PE as the first option in the treatment of HUS.
出处 《中国小儿急救医学》 CAS 2012年第4期390-392,共3页 Chinese Pediatric Emergency Medicine
关键词 血浆置换 溶血尿毒综合征 儿童 Plasma exchange Hemolytic uremic syndrome Children
  • 相关文献

参考文献6

二级参考文献57

  • 1熊建琼,邓朝霞,谢先会,文亮.连续性血液净化治疗在多器官功能障碍综合征中的应用[J].重庆医学,2006,35(3):250-251. 被引量:19
  • 2<血管紧张素转换酶抑制剂在肾脏病中正确应用>专家协会组.血管紧张素转换酶抑制剂在肾脏病中正确应用的专家共识[J].中华肾脏病杂志,2006,22(1):57-58. 被引量:70
  • 3叶礼燕,余自华,黄祖雄,陈新民,任榕娜,陈光明,王承峰,夏桂枝,黄隽,王芳建.溶血性尿毒症综合征急性期后治疗探讨[J].中华儿科杂志,2006,44(3):206-209. 被引量:2
  • 4Bell WR, Braine FIG, Ness PM, et al. Improved survival in thrombotic thrombocytopenic purpra-hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med, 1991, 325(6) :398- 403.
  • 5HoIlenbeck M, Kutkuhn B, Aul C. Haemolytic uraemie syndrome and thrombotic thrombocy-topenic purpura in adaltstclinical findings and prognostic factors for death and end-stage renal disease. Nephrol Dial Transplant, 1998, 13(1):76-81.
  • 6Darmon M, Azoulay E, Thiery G, et al. Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit Care Med, 2006, 34 (8):2127-2133.
  • 7Allford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic mieroangiopathie haemolytie anaemias. Br J Haematol, 2003,120(4) : 556-573.
  • 8Amirlak I,Amirlak B.Haemolytic uremic syndrome:an overview[J].Nephrology,2006,11(3):213.
  • 9Tsai HM.The molecular biology of thrombotic microangiopathy[J].Kidney International,2006,70(1):16.
  • 10Fang CJ,Richards A,Liszewski MK,et al.Advances in understanding of pathogenesis of aHUS and HELLP[J].Br J Haematol,2008,143(3):336.

共引文献24

同被引文献42

  • 1JANKA G E. Familial and acquired hemophagocytic lymphohistio- cytosis [ J ]. Eur J Pediatr,2007,166 : 95 - 109.
  • 2Joseph S, Jeffrey LW, Anand P, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Ap- proach from the Writing Committee of the American Society for Apheresis The Sixth Special Issue [ J ]. J Clin Apher, 2013,28 ( 3 ) : 145-284.
  • 3Noris M,Remuzzi G. Atypical hemolytic-uremic syndrome[ J]. N Engl J Med,2009,22,361 (17) :1676-1687.
  • 4Sanchez AP, Ward DM. Therapeutic apheresis for renal disor- ders[ J]. Semin Dial ,2012,25 (2) : 119-131.
  • 5Banatvala N, Griffin PM, Greene KD, et al. The United States National Prospective Hemolytic Uremic Syndrome Study:micro- biologic, serologic, clinical, and epidemiologic finding [ J ]. J Infect Dis, 2001,183 ( 7 ) : 1063 -1070.
  • 6Brunskill S J, Tusold A, Benjamin S, et al. A systematic review of randomized controlled trials for plasma exchange in the treat- ment of thrombotic thrombocytopenic purpura [ J ]. Transfus Med ,2007,17 ( 1 ) : 17-35.
  • 7Levy JB, Turner AN, Rees A J, et al. Long-term outcome of anti- glomerular basement membrane antibody disease treated with plasma exchange and [ J ]. Ann Intern Med 2001,134( 11 ) :1033-1042.
  • 8Dada MA, Kaplan AA. Plasmapheresis treatment in Guillaln- Barre syndrome:potential benefit over IVIg in patients with ax- onal involvement [ J ]. Ther Apher Dial,2004,8 (5) :409-412.
  • 9Szczeklik W, Jankowski M, Wegrzyn W, et al. Acute respiratory failure in patients with Gtullain-Barre syndrome and myasthenic crisis treated with plasmapheresis in the intensive care unite[ J]. Pol Arch Med Wewn,2008,118(4) :239-242.
  • 10Robert WT. Therapeutic apheresis in neurological disorders: a survey of the evidence in support of current category i and ii in- dications for therapeutic plasma exchange [ J ]. J Clin Apher, 2008,23 ( 6 ) : 196-201.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部